Generate Biomedicines, Inc. (GENB) stock
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)
Close on Nov 17, 2026Market cap $1.26BP/E –Yield –
Generate Biomedicines ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$87.81M | – |
| Q2 FY2026 | Jun 30, 2026 | -$68.41M | – |
| Q1 FY2026 | Mar 31, 2026 | -$60.84M | – |
| Q3 FY2025 | Sep 30, 2025 | -$59.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$56.85M | – |
| Q1 FY2025 | Mar 31, 2025 | -$44.74M | – |
See a number that looks wrong?